Another well thought out article,they spelled the name of the company and the product wrong.
New York, NY – (NISMAGAZINE) – 3/19/2013- Mankind Corp (NASDAQ:MNKD) moved northwards by 0.59% to close at $3.40 in the Monday’s trading session with volumes of 6.81Million. The average trading volume of the stock is 3.93Million. On Monday, the stock touched high of $3.49 and low of $3.15. MNKD surged 35.46% in the month. MNKD’s Afrezza is a blockbuster drug in making; however, betting on the stock right now would be too early. Afrezza is an inhalable insulin, soon to become MNKD’s one of the leading products. Though Afrezza is in its late Phase III clinical studies, yet a delay in approval is could also be a possibility. MannKind Corp. is a biopharmaceutical company which deals with the development and commercialization of therapeutic products. Regulatory risks & clinical trials plague the company.
http://www.nismagazine.com/afreeza-to-decide-future-course-of-action-for-mankind-corp-nasdaqmnkd-fnfg-ozm/122790/
